Clinical Trial Search

Phase 3 N=645 Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

Metastatic Cancer · Prostate Cancer

Primary: Time to First Skeletal Related Event — 31.9; 28.8 months — p=0.385

Alliance for Clinical Trials in Oncology Results Oct 2014 19.6% serious AE View details

Phase 3 N=175 Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects

Sedation

Primary: Percentage of Subjects That do Not Require Rescue Midazolam (MDZ) for Sedation Based on Achieving and Maintaining a Target University of Michigan Sedation Scale (UMSS)…

Hospira, now a wholly owned subsidiary of Pfizer Results Oct 2014 1.1% serious AE View details

Phase 3 N=279 Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Diabetes · Diabetes Mellitus, Type 2

Primary: Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin) — -1.05…

Novo Nordisk A/S Results Oct 2014 10.5% serious AE View details

Phase 3 N=492 A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks — -1.43; 0.14; -1.33 percentage of HbA1c — p=<0.001

Eli Lilly and Company Results Oct 2014 4.3% serious AE View details

Phase 3 N=689 CONNECT for Better Falls Prevention in VA Community Living Centers

Accidental Falls

Primary: Fall-related Process Measures — 0.40; 0.32 proportion of indicators completed

US Department of Veterans Affairs Results Oct 2014 0.0% serious AE View details

Phase 3 N=575 A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease

Dyslipidemia

Primary: Percentage of Change of TG (Triglyceride) — -30.6; 10.7; -27.3; -2.9 percentage of change

Abbott Results Oct 2014 2.3% serious AE View details

Phase 3 N=239 An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)

Urticaria

Primary: Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2 — -3.19; -3.16; -2.02 Score on a Scale — p=<0.001

Organon and Co Results Oct 2014 0.0% serious AE View details

Phase 3 N=106 A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Hepatitis C Virus Genotype-1

Primary: Percentage of Participants With Sustained Virologic Response at Week 12 (SVR 12) — 73.6 percentage of participants

Janssen R&D Ireland Results Oct 2014 10.4% serious AE View details

Phase 3 N=39 Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation

Cystic Fibrosis

Primary: Part 1: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8 — 76.3659; 79.3361; 8.1308; -5.8738 percent…

Vertex Pharmaceuticals Incorporated Results Oct 2014 12.6% serious AE View details

Phase 3 N=286 Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

Purulent Bacterial Conjunctivitis

Primary: The Primary Efficacy Variable Was Clinical Cure in the Worse Eye on Day 3 — 48; 29 participants

Laboratoires Thea Results Oct 2014 0.0% serious AE View details

Phase 3 N=36 A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.

Heart Transplantation

Primary: Percentage of Participants With Biopsy Proven Acute Rejection (BPAR) by Week — 0.0; 0.0; 2.78; 2.78 percentage of participants

Hoffmann-La Roche Results Oct 2014 5.6% serious AE View details

Phase 3 N=330 A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer

Breast Cancer

Primary: Event-Free Survival (EFS) - Percentage of Participants With an Event — 40.0; 50.9; 42.4 percentage of participants

Hoffmann-La Roche Results Oct 2014 10.7% serious AE View details

Phase 3 N=33 Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

Hypophosphatemia, Familial · Hyperparathyroidism

Primary: Area Under the Curve for Parathyroid Hormone (PTHauc) Measurement — 1223; 1449; 987; 1616 nlEq*26hr/ml — p=0.007

Yale University Results Oct 2014 0.0% serious AE View details

Phase 3 N=698 Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

HIV · HIV Infections

Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 — 85.2; 87.4 percentage of participants

Gilead Sciences Results Oct 2014 16.5% serious AE View details

Phase 3 N=451 The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Diabetes · Diabetes Mellitus, Type 2

Primary: Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26 — -1.30; -0.11 percentage of glycosylated haemoglobin — p=<0.0001

Novo Nordisk A/S Results Oct 2014 4.0% serious AE View details